NCT05775471View on ClinicalTrials.gov

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
PROCEDURE

Biopsy

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood and urine collection

DRUG

Enfortumab Vedotin

Given IV

PROCEDURE

MR Urography

Undergo MRU

PROCEDURE

Nephroureterectomy

Undergo nephroureterectomy

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Seagen Inc.

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER